Genitourinary Medical Oncology

Outpatient consultations at the Genitourinary Medical Oncology Unit take place from Monday to Friday, between 8.30 am and 5.00 pm, on the 2nd floor of Block E.

Initial consultations: Monday mornings and Friday mornings (depending on the specific condition)

Follow-up consultations: available every day, from Monday to Friday

Teleconsultations: Thursdays

Medical staff may carry out private practice within the hospital, in accordance with internal regulations.

Outpatient appointments, whether under the National Health Service (NHS) or as private practice, can be booked via the Institute’s General Outpatient Booking Centre (CUP), by visiting the counters on the ground floor of Block C or by calling +39 02 23901 during the following hours: 7.30am–4.30pm Monday to Friday, and 8.30am–12.30pm on Saturdays.

For NHS bookings, you must have your NHS card.

For private practice appointments, online booking is also available via the link:

The Department of Genitourinary Medical Oncology specialises in the diagnosis and treatment of malignant tumours of the male urinary and genital systems.

Treatment plans are developed through multidisciplinary collaboration with radiotherapists, urologists, radiologists, nuclear medicine specialists and pathologists, to offer each patient a personalised treatment pathway and access to innovative therapies.

Prostate cancer: this is a very common condition, particularly in older men. 

Early diagnosis allows for a watch-and-wait approach in low-risk cases, which can benefit from a ‘watch-and-wait’ strategy whilst preserving quality of life; meanwhile, for patients with advanced forms of the disease, new-generation hormonal therapies, chemotherapy, molecularly targeted drugs (e.g. PARP inhibitors) and innovative radiotherapies (radium and lutetium-PSMA), with a significant impact in terms of improved survival and quality of life.

Kidney cancer: a condition with a low incidence in the general population, accounting for around 2% of all cancers, which requires a high level of specialisation for appropriate clinical management.

Over the last decade, new drugs, such as tyrosine kinase inhibitors and immunotherapy, and strategies combining these, have significantly improved the prognosis. 

Urothelial cancer: very common, particularly in low-grade forms. It is managed in close collaboration with urologists to provide integrated treatments aimed at preserving the organ.

Germ cell tumours: these mainly affect young people and require careful management for early detection and treatment of relapses, surgical preservation of the organ and fertility, with a focus on long-term follow-up.

Adrenocortical tumour: a very rare tumour requiring integrated management by expert oncologists and endocrinologists. Clinical research is opening up new therapeutic prospects.